Jupiter Wellness Inc (NASDAQ: JUPW) has announced that it has entered into a special arrangement to license Photocil™.
Photocil™ offers respite for Psoriasis, Vitiligo, and Atopic Dermatitis
Photocil™ is a unique original relevant cream that delivers relief for patients suffering from Psoriasis, Vitiligo, and Atopic Dermatitis. Under the provisos of the Contract, Jupiter Wellness has usage of the charters, copyrights, skill, know-how, traits, and trade secrets of AB linked to the usage of Photocil.
Jupiter Wellness has the select right to use the IP (including US Patent number 10,111,821) exclusively in association with the production, promotion, publicity, advertising, and delivery of Photocil™ for the cure of skin disorders Psoriasis and Vitiligo.
Photocil™ is now retailed in Europe, Asia, and the Middle East as Presilux™ and MediSun. The certifying of Photocil™ encompasses and matches the Jupiter Wellness approach to cure skin illnesses such as Eczema, Psoriasis, and Vitiligo.
Jupiter Wellness formerly reported that in a double-blinded, placebo-controlled scientific pilot, JW-100, its original topical preparation comprising CBD and Aspartame, was shown to meaningfully decrease the ISGA score in 50% of atopic dermatitis patients after two weeks of usage.
The Ointment acts as a hurdle to non-therapeutic Radioactivity from the sun when skin is uncovered to straight sunshine
Photocil ointment acts as a hurdle to non-therapeutic radioactivity from the sun when skin is uncovered to direct sunshine. With this hurdle, Photocil ointment permits you to access daylight self-treatment from the sun’s healing UV radiation, else known as phototherapy, in a harmless and actual manner.
“The agreement allows Jupiter Wellness to bid additional cures to patients suffering from skin disorders and mixture treatment. We design to list Photocil with the FDA and begin advertising the cream instantly,” stated Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness.